Drug intelligence / Profile preview

YB-821

Development stage: Preclinical
Lead developer: Ymmunobio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

YB-821 is a preclinical-stage bispecific T-cell engager (BiTCE) being developed by Ymmunobio for the treatment of solid tumors. The therapeutic candidate is designed to target neuronal pentraxin receptor (NPTXR), a protein overexpressed in various solid tumors, and CD3 on T cells. By simultaneously binding to NPTXR on tumor cells and CD3 on T lymphocytes, YB-821 redirects and activates T cells to selectively eliminate NPTXR-positive cancer cells via immune-mediated cytotoxicity.

Targets

CD3 (T-cell surface glycoprotein CD3)NPTXR (Neuronal pentraxin receptor)

Beyond the preview

Go deeper on YB-821.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YB-821.

Explore the full profile